Two Single Nucleotide Polymorphisms in the Purinergic Receptor P2X7 Gene Are Associated with Disease Severity in Multiple Sclerosis
- PMID: 36499708
- PMCID: PMC9736555
- DOI: 10.3390/ijms232315381
Two Single Nucleotide Polymorphisms in the Purinergic Receptor P2X7 Gene Are Associated with Disease Severity in Multiple Sclerosis
Abstract
Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous system (CNS) that leads to progressive physical disability. Recent evidence has suggested that P2X7 receptor (P2X7R)-mediated purinergic signalling pathways play a role in MS-associated neuroinflammation, possibly contributing to disease pathogenesis. To evaluate possible associations between P2X7R polymorphisms and MS disease severity, we performed an association study of five non-synonymous SNPs coding variants of the P2X7R gene: rs1718119 Ala348Thr, rs2230911 Thr357Ser, rs2230912 Gln460Arg, rs3751143 Glu496Ala, and rs28360457 Arg307Gln, modulating P2X7R expression in 128 MS patients (relapsing remitting MS, RRMS: n = 94; secondary progressive, SPMS: n = 34). All patients were genotyped, and multiple sclerosis severity score (MSSS) was evaluated in every case; 189 healthy subjects were enrolled as well as controls. Results showed that P2X7R rs1718119(A) 348Thr and rs22390912(G) 464Arg, two SNPs of minor allele frequency (MAF) known to confer gain of function to the P2X7R protein, were associated with significantly higher MSSS in RRMS patients alone (SMRR (p < 0.001, p = 0.01, respectively)). Interestingly, two whole haplotypes resulted in having significant association with MSSS in these same patients. Thus: (1) the P2X7R-4 “ACGAG” haplotype, characterized by the co-presence of the rs1718119-rs2230912 AG MAF alleles, was associated with higher MSSS (Beta: 1.11 p = 0.04), and (2) the P2X7R-1 “GCAAG” complementary haplotype, which contains the rs1718119 and rs2230912 GA wild-type alleles, was more frequently carried by patients with lower MSSS and less severe disease (Beta: −1.54 p < 0.001). Although being preliminary and needing confirmation in an ampler cohort, these results suggest that 348Thr and 464Arg variants have a role as modulators of disease severity in RRMS patients.
Keywords: P2X7 receptor polymorphisms; multiple sclerosis; multiple sclerosis severity score; purinergic receptor.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Association of purinergic receptor P2RX7 gene polymorphisms with depression symptoms.Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jun 8;92:207-216. doi: 10.1016/j.pnpbp.2019.01.006. Epub 2019 Jan 19. Prog Neuropsychopharmacol Biol Psychiatry. 2019. PMID: 30664971
-
Genetic interaction of purinergic P2X7 receptor and ER-α polymorphisms in susceptibility to osteoporosis in Chinese postmenopausal women.J Bone Miner Metab. 2018 Jul;36(4):488-497. doi: 10.1007/s00774-017-0862-3. Epub 2017 Sep 7. J Bone Miner Metab. 2018. PMID: 28884379
-
Purinergic P2X7 receptor functional genetic polymorphisms are associated with the susceptibility to obesity in Chinese postmenopausal women.Menopause. 2018 Mar;25(3):329-335. doi: 10.1097/GME.0000000000000991. Menopause. 2018. PMID: 29088017
-
Correlation between P2X7 receptor gene polymorphisms and gout.Rheumatol Int. 2015 Aug;35(8):1307-10. doi: 10.1007/s00296-015-3258-5. Epub 2015 Mar 24. Rheumatol Int. 2015. PMID: 25800962 Review.
-
The role of vitamin D and P2X7R in multiple sclerosis.J Neuroimmunol. 2019 May 15;330:159-169. doi: 10.1016/j.jneuroim.2019.03.004. Epub 2019 Mar 14. J Neuroimmunol. 2019. PMID: 30908981 Review.
Cited by
-
P2X7 receptors and multiple sclerosis: A potential biomarker and therapeutic target?Neural Regen Res. 2026 Jan 1;21(1):318-319. doi: 10.4103/NRR.NRR-D-24-01115. Epub 2024 Dec 16. Neural Regen Res. 2026. PMID: 39688571 Free PMC article. No abstract available.
-
The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigm.Front Immunol. 2025 Apr 16;16:1554999. doi: 10.3389/fimmu.2025.1554999. eCollection 2025. Front Immunol. 2025. PMID: 40308584 Free PMC article.
-
New insights into pathogenisis and therapies of P2X7R in Parkinson's disease.NPJ Parkinsons Dis. 2025 May 5;11(1):108. doi: 10.1038/s41531-025-00980-7. NPJ Parkinsons Dis. 2025. PMID: 40325043 Free PMC article. Review.
-
P2X7 Variants in Pathophysiology.Int J Mol Sci. 2024 Jun 18;25(12):6673. doi: 10.3390/ijms25126673. Int J Mol Sci. 2024. PMID: 38928378 Free PMC article. Review.
-
Role of the P2 × 7 receptor in neurodegenerative diseases and its pharmacological properties.Cell Biosci. 2023 Dec 13;13(1):225. doi: 10.1186/s13578-023-01161-w. Cell Biosci. 2023. PMID: 38093352 Free PMC article. Review.
References
-
- Walton C., King R., Rechtman L., Kaye W., Leray E., Marrie R.A., Robertson N., La Rocca N., Uitdehaag B., van der Mei I., et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult. Scler. 2020;26:1816–1821. doi: 10.1177/1352458520970841. - DOI - PMC - PubMed
-
- Lopes Pinheiro M.A., Kooij G., Mizee M.R., Kamermans A., Enzmann G., Lyck R., Schwaninger M., Engelhardt B., de Vries H.E. Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke. Biochim. Biophys. Acta. 2016;1862:461–471. doi: 10.1016/j.bbadis.2015.10.018. - DOI - PubMed